{"title": "A prospect on the use of antiviral drugs to control local outbreaks of COVID-19", "doi": "10.1101/2020.03.19.20038182", "citation_id": "2020.03.19.20038182v1", "date": "2020-03-20", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.19.20038182", "abstract": "<p>Objective: Investigate the impact of using antiviral drugs to control local outbreaks of COVID-19.\nMethods: Using a simulation-based model of viral transmission we tested the impact of different intervention measures for the control of COVID-19.\nResults: The use of an antiviral drug, in combination with contact tracing, quarantine and isolation, results in a significant decrease of the mean final size and the peak incidence of local outbreaks of COVID-19, provided delays in contact tracing are small. \nConclusions: Integrating antiviral drugs together with contact tracing and quarantine is predicted through this model to be an effective tool for the control  of local outbreaks of COVID-19.</p>", "twitter_description": "Objective: Investigate the impact of using antiviral drugs to control local outbreaks of COVID-19. Methods: Using a simulation-based model of viral transmission we tested the impact of different intervention measures for the control of COVID-19. Results: The use of an antiviral drug, in combination with contact tracing, quarantine and isolation, results in a significant decrease of the mean final size and the peak incidence of local outbreaks of COVID-19, provided delays in contact tracing are small. Conclusions: Integrating antiviral drugs together with contact tracing and quarantine is predicted through this model to be an effective tool for the control of local outbreaks of COVID-19.\n\n### Competing Interest Statement\n\nBesides his employment at the Hasselt University, JV is employed at Bioqube Ventures. Bioqube Ventures was not involved in this work, nor does it prosper financially as a result of the current study. The other authors declare that they have no competing interests.\n\n### Funding Statement\n\nThis work is funded by the Epipose project from the European Union\u0092s SC1-PHE-CORONAVIRUS-2020 programme, project number 101003688 and by the European Union\u0092s Horizon 2020 research and innovation programme (grant agreement 682540 \u0097 TransMID). AT acknowledges support from the special research fund of the University of Antwerp. PL was supported by funding from the Flemish Government under the \"Onderzoeksprogramma Artificiele Intelligentie (AI) Vlaanderen\" programme.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nOur study concerns the modelling of antiviral compounds to contain COVID-19 epidemics. Our modelling code has been posted to github.\n\n<https://github.com/AndreaTorneri/ViralTransm>", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038182v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038182v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038182v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.19.20038182.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.19.20038182v1", "access_rights": "restricted", "authors": ["Andrea Torneri", "Pieter Jules Karel Libin", "Joris Vanderlocht", "Anne-Mieke Vandamme", "Johan Neyts", "Niel Hens"]}